QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tawab, M. A. Articles by Schubert-Zsilavecz, M. Search for Related Content PubMed PubMed Citation Articles by Tawab, M. A. Articles by Schubert-Zsilavecz, M.

DEGRADATION OF GINSENOSIDES IN HUMANS AFTER ORAL ADMINISTRATION

Institute of Pharmaceutical Chemistry, Johann Wolfgang Goethe University, Frankfurt, Germany

Even though the degradation of ginsenosides has been thoroughly studied in animals and in vitro using acids, enzymes, and intestinal bacteria, knowledge concerning the systemic availability of ginsenosides and their degradation products in humans is generally lacking. Therefore, the attention in this article is focused on the identification of ginsenosides and their hydrolysis products reaching the systemic circulation in man. This is of great importance in understanding clinical effects, preventing herb-drug interactions, and optimizing the biopharmaceutical properties of ginseng preparations. Using a sensitive mass spectrometric method, which is specific for the identification of ginsenosides in complex biological matrices, the degradation pathway of ginsenosides in the gastrointestinal tract of humans could be elucidated following the oral administration of ginseng. Within the frame of a pilot study, human plasma and urine samples of two subjects were screened for ginsenosides and their possible degradation products. In general, the urine data coincided well with the plasma data. In both volunteers the same hydrolysis products, which are not originally present in the Ginsana extract (Pharmaton S.A., Lugano, Switzerland) ingested, were identified in plasma and urine. It was shown that two hydrolysis products of the protopanaxatriol ginsenosides, namely G-Rh₁ and G-F₁ may reach the systemic circulation. In addition, compound-K, the main intestinal bacterial metabolite of the protopanaxadiol ginsenosides, was detected in plasma and urine. These products are probably responsible for the action of ginseng in humans. In opposition to previous reports, G-Rb₁ was identified in plasma and urine of one subject.

This article has been cited by other articles:

				L. S. Lee, S. D. Wise, C. Chan, T. L. Parsons, C. Flexner, and P. S. Lietman Possible Differential Induction of Phase 2 Enzyme and Antioxidant Pathways by American Ginseng, Panax quinquefolius J. Clin. Pharmacol., May 1, 2008; 48(5): 599 - 609. [Abstract] [Full Text] [PDF]

				Y. Liu, J.-W. Zhang, W. Li, H. Ma, J. Sun, M.-C. Deng, and L. Yang Ginsenoside Metabolites, Rather Than Naturally Occurring Ginsenosides, Lead to Inhibition of Human Cytochrome P450 Enzymes Toxicol. Sci., June 1, 2006; 91(2): 356 - 364. [Abstract] [Full Text] [PDF]

				P. M. Stavro, M. Woo, L. A. Leiter, T. F. Heim, J. L. Sievenpiper, and V. Vuksan Long-Term Intake of North American Ginseng Has No Effect on 24-Hour Blood Pressure and Renal Function Hypertension, April 1, 2006; 47(4): 791 - 796. [Abstract] [Full Text] [PDF]